In this setting up, it was shown that autologous DCs loaded with tumor antigens are safe and capable of inducing tumor antigen-specific immune responses in a substantial part of the vaccinated patients (26)

In this setting up, it was shown that autologous DCs loaded with tumor antigens are safe and capable of inducing tumor antigen-specific immune responses in a substantial part of the vaccinated patients (26). regulating the immune response within the tumor microenvironment. In particular, possible therapeutic intervention strategies aimed at reversing or neutralizing suppressive networks within the tumor microenvironment will be emphasized. Importantly, blocking co-inhibitory molecule signaling, often referred to as immune checkpoint blockade, does not necessarily lead to an effective activation of tumor-specific T cells. Therefore, combination of checkpoint blockade with other immune potentiating therapeutic strategies, such as DC vaccination, might serve as a synergistic combination, capable of reversing effector T cells immunosuppression while at the same time increasing the efficacy Ofloxacin (DL8280) of T cell-mediated immunotherapies. This will ultimately result in long-term anti-tumor immunity. Keywords:DC vaccination, tumor microenvironment, checkpoint blockade, tumor-specific T cells, cancer treatment Ofloxacin (DL8280) == Introduction == The goal of cancer immunotherapy is usually to activate, or reactivate, the immune system in cancer patients for therapeutic benefit. This is a GluA3 challenging endeavor, as escape from immunosurveillance is an essential requirement for tumor progression. Early tumors can be eliminated or contained by the immune system but, by a process involving immunoediting, tumor cells can Ofloxacin (DL8280) eventually escape this detection (1). They do so by hiding from immune detection, blocking the function of immune cells, and/or by influencing immune cells to induce tolerance to the tumor and even to produce tumor growth enhancing factors. Despite this escape from immunosurveillance, there is ample evidence indicating that it is possible to induce specific anti-tumor immune responses either naturally (spontaneous) or therapeutically. This requires a number of discrete actions. Firstly, dendritic cells (DCs) must take up and present antigens derived from the tumor, which can be encounteredin situor delivered to the DCsex vivoas a part of a therapeutic vaccine. This has to be coupled to an activation or maturation signal to the DC. Next, these mature tumor antigen presenting DCs migrate toward the lymphoid organs, where they have to induce antigen-specific T cell responses that target the tumor (2,3). Efficient anti-tumor responses are Ofloxacin (DL8280) believed to require CD8+cytotoxic (killer) T cells, but recent data indicate that induction of CD4+T helper cells also contribute to clinical efficacy (4). Conversely, DCs may also trigger antibody and natural killer (NK) cell responses, which can contribute to anti-tumor immunity (5,6). Priming of nave T cells into antigen-specific effector T cells by DCs requires four signals (Physique1): (I) engagement of a T cell receptor (TCR) with a peptide-major-histocompatibility Ofloxacin (DL8280) complex (MHC) around the DC and (II) the right balance between expression of co-stimulatory molecules that activate T cell proliferation and co-inhibitory molecules that attenuate T cell activation on both cell types. (III) A third signal is usually provided by cytokines secreted by the DCs, which promote T cell differentiation and polarization toward specific effector T cell phenotypes. Finally (IV), DCs regulate the induction of specific chemokine receptors and integrins on T cells to direct migration toward specific tissues (2,710). == Physique 1. == Dendritic cell vaccination is usually counteracted by host immunosuppressive mechanisms. Monocytes or natural occurring dendritic cells are isolated from the peripheral blood of the patient, loaded with tumor antigens, and subsequently matured. These activated DCs are re-infused into the patient and migrate to the lymph node to encounter and interact with nave T cells in order to induce the activation of effector T cells. DC-mediated T cell activation is usually regulated by four signals: (I) conversation between TCR on T cells and MHC:peptide complex, (II) co-stimulation via CD28 and CD80/86 expressed on T cells and DCs respectively, (III) secretion of pro-inflammatory cytokines such as IFNs and IL-12, and (IV) release of DC-processed metabolites. These activated CD8+cytotoxic T cells and CD4+T helper cells migrate to the tumor site where they are eventually.